KYVERNA THERAPEUTICS INC (KYTX) Stock Price & Overview
NASDAQ:KYTX • US5019761049
Current stock price
The current stock price of KYTX is 8.98 USD. Today KYTX is up by 1.24%. In the past month the price increased by 10.86%. In the past year, price increased by 335.92%.
KYTX Key Statistics
- Market Cap
- 513.027M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.65
- Dividend Yield
- N/A
KYTX Stock Performance
KYTX Stock Chart
KYTX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to KYTX. When comparing the yearly performance of all stocks, KYTX is one of the better performing stocks in the market, outperforming 98.27% of all stocks.
KYTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KYTX. KYTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
KYTX Earnings
KYTX Forecast & Estimates
12 analysts have analysed KYTX and the average price target is 28.76 USD. This implies a price increase of 220.31% is expected in the next year compared to the current price of 8.98.
KYTX Groups
Sector & Classification
KYTX Financial Highlights
Over the last trailing twelve months KYTX reported a non-GAAP Earnings per Share(EPS) of -3.65. The EPS decreased by -5.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.9% | ||
| ROE | -69.45% | ||
| Debt/Equity | 0.11 |
KYTX Ownership
KYTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.93 | 365.463B | ||
| AMGN | AMGEN INC | 15.01 | 184.669B | ||
| GILD | GILEAD SCIENCES INC | 15.85 | 173.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 110.325B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.32 | 80.669B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.27 | 43.81B | ||
| INSM | INSMED INC | N/A | 35.309B | ||
| NTRA | NATERA INC | N/A | 29.036B | ||
| BIIB | BIOGEN INC | 10.72 | 25.293B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.74 | 24.53B | ||
| MRNA | MODERNA INC | N/A | 19.261B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.898B | ||
| INCY | INCYTE CORP | 12.39 | 18.878B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KYTX
Company Profile
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company is headquartered in Emeryville, California and currently employs 129 full-time employees. The company went IPO on 2024-02-08. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The firm is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
Company Info
IPO: 2024-02-08
KYVERNA THERAPEUTICS INC
5980 Horton Street, Suite 550
Emeryville CALIFORNIA US
Employees: 129
Phone: 15106268331
KYVERNA THERAPEUTICS INC / KYTX FAQ
What does KYTX do?
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company is headquartered in Emeryville, California and currently employs 129 full-time employees. The company went IPO on 2024-02-08. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The firm is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
What is the current price of KYTX stock?
The current stock price of KYTX is 8.98 USD. The price increased by 1.24% in the last trading session.
Does KYTX stock pay dividends?
KYTX does not pay a dividend.
What is the ChartMill rating of KYVERNA THERAPEUTICS INC stock?
KYTX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the market capitalization of KYTX stock?
KYVERNA THERAPEUTICS INC (KYTX) has a market capitalization of 513.03M USD. This makes KYTX a Small Cap stock.
Can you provide the upcoming earnings date for KYVERNA THERAPEUTICS INC?
KYVERNA THERAPEUTICS INC (KYTX) will report earnings on 2026-05-11.